Enanta Pharmaceuticals (NASDAQ:ENTA – Get Free Report) is one of 894 public companies in the “Pharmaceuticals” industry, but how does it contrast to its rivals? We will compare Enanta Pharmaceuticals to related businesses based on the strength of its valuation, institutional ownership, analyst recommendations, earnings, profitability, risk and dividends.
Analyst Ratings
This is a breakdown of current ratings and price targets for Enanta Pharmaceuticals and its rivals, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Enanta Pharmaceuticals | 1 | 0 | 2 | 0 | 2.33 |
| Enanta Pharmaceuticals Competitors | 7845 | 13797 | 25807 | 1039 | 2.41 |
Enanta Pharmaceuticals presently has a consensus price target of $20.00, indicating a potential upside of 81.98%. As a group, “Pharmaceuticals” companies have a potential upside of 24.25%. Given Enanta Pharmaceuticals’ higher probable upside, analysts clearly believe Enanta Pharmaceuticals is more favorable than its rivals.
Valuation & Earnings
This table compares Enanta Pharmaceuticals and its rivals revenue, earnings per share and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Enanta Pharmaceuticals | $65.32 million | -$81.89 million | -4.56 |
| Enanta Pharmaceuticals Competitors | $18.33 billion | $3.19 billion | 562.76 |
Enanta Pharmaceuticals’ rivals have higher revenue and earnings than Enanta Pharmaceuticals. Enanta Pharmaceuticals is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.
Profitability
This table compares Enanta Pharmaceuticals and its rivals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Enanta Pharmaceuticals | -96.89% | -61.84% | -20.70% |
| Enanta Pharmaceuticals Competitors | -2,398.26% | -203.62% | -15.08% |
Institutional & Insider Ownership
95.0% of Enanta Pharmaceuticals shares are owned by institutional investors. Comparatively, 32.7% of shares of all “Pharmaceuticals” companies are owned by institutional investors. 11.5% of Enanta Pharmaceuticals shares are owned by company insiders. Comparatively, 14.2% of shares of all “Pharmaceuticals” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Risk and Volatility
Enanta Pharmaceuticals has a beta of 0.75, indicating that its stock price is 25% less volatile than the S&P 500. Comparatively, Enanta Pharmaceuticals’ rivals have a beta of -0.04, indicating that their average stock price is 104% less volatile than the S&P 500.
Summary
Enanta Pharmaceuticals rivals beat Enanta Pharmaceuticals on 7 of the 13 factors compared.
About Enanta Pharmaceuticals
Enanta Pharmaceuticals, Inc. is a biotechnology company based in Watertown, Massachusetts, that discovers and develops small-molecule medicines. Its research has focused on infectious diseases and inflammatory conditions, including respiratory syncytial virus (RSV), hepatitis B and immunology. Enanta’s work with AbbVie contributed to the discovery of glecaprevir, an antiviral used with pibrentasvir in the hepatitis C treatment Mavyret. The collaboration reflects the company’s history of applying its drug-discovery expertise to antiviral therapies.
Receive News & Ratings for Enanta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enanta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
